Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity

Vaccine

Volumn 24, Issue 12, 2006, Pages 2102-2109

  Cornet, Sébastien ^a   Miconnet, Isabelle ^a   Menez, Jeanne ^a   Lemonnier, François ^b   Kosmatopoulos, Kostas ^a  

^a Vaxon Biotech   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Cryptic peptides; Polypeptide; Tumor vaccination

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MELANOMA ANTIGEN; POLY 1 METHIONYLASPARAGINYLTHREONINAMIDE; POLY 2 METHIONYLTHREONYLASPARAGINAMIDE; POLY 3 ASPARAGINYLTHREONYLMETHIONINAMIDE; POLY 4 ASPARAGINYLMETHIONYLTHREONINAMIDE; POLY 5 THREONYLASPARAGINYLMETHIONINAMIDE; POLY 6 THREONYLMETHIONYLASPARAGINAMIDE; POLYPEPTIDE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; TRANSGENIC MOUSE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; MICE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; VACCINES, COMBINED; VACCINES, SUBUNIT;

EID: 32844457624     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.11.015     Document Type: Article

References (36)

1. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat Med 10 9 2004 909 915
2. P.F. Robbins, and Y. Kawakami Human tumor antigens recognized by T cells Curr Opin Immunol 8 5 1996 628 636
3. A. Van Pel, P. van der Bruggen, P.G. Coulie, V.G. Brichard, B. Lethe, and B. van den Eynde Genes coding for tumor antigens recognized by cytolytic T lymphocytes Immunol Rev 145 1995 229 250
4. N.P. Restifo Hierarchy, tolerance, and dominance in the antitumor T-cell response J Immunother 24 3 2001 193 194
5. R. Cibotti, J.M. Kanellopoulos, J.P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, and E. Sercarz Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants Proc Natl Acad Sci USA 89 1 1992 416 420
6. N.K. Nanda, and E.E. Sercarz Induction of anti-self-immunity to cure cancer Cell 82 1 1995 13 17
7. D.A. Gross, S. Graff-Dubois, P. Opolon, S. Cornet, P. Alves, and A. Bennaceur-Griscelli High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy J Clin Invest 113 3 2004 425 433
8. F. Lehmann, M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, and H. Ikeda Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection Eur J Immunol 25 2 1995 340 347
9. F. Brasseur, D. Rimoldi, D. Lienard, B. Lethe, S. Carrel, and F. Arienti Expression of MAGE genes in primary and metastatic cutaneous melanoma Int J Cancer 63 3 1995 375 380
10. M. Oukka, J.C. Manuguerra, N. Livaditis, S. Tourdot, N. Riche, and I. Vergnon Protection against lethal viral infection by vaccination with nonimmunodominant peptides J Immunol 157 7 1996 3039 3045
11. D.M. Reese, and D.J. Slamon HER-2/neu signal transduction in human breast and ovarian cancer Stem Cells 15 1 1997 1 8
12. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 1987 177 182
13. R.H. Vonderheide, W.C. Hahn, J.L. Schultze, and L.M. Nadler The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes Immunity 10 6 1999 673 679
14. B. Minev, J. Hipp, H. Firat, J.D. Schmidt, P. Langlade-Demoyen, and M. Zanetti Cytotoxic T cell immunity against telomerase reverse transcriptase in humans Proc Natl Acad Sci USA 97 9 2000 4796 4801
15. B.J. Van den Eynde, and P. van der Bruggen T cell defined tumor antigens Curr Opin Immunol 9 5 1997 684 693
16. S. Ofuji, M. Ikeda, S. Tsujitani, M. Ikeguchi, N. Kaibara, and I. Yuasa Expression of MAGE-1, MAGE-2 and MAGE-3 genes in human gastric carcinomas; lack of evidence for cytotoxic effects in cases with simultaneous expression of MAGE-3 and HLA-A2 Anticancer Res 18 5B 1998 3639 3644
17. S. Ogata, H. Uehara, A. Chen, and S.H. Itzkowitz Mucin gene expression in colonic tissues and cell lines Cancer Res 52 21 1992 5971 5978
18. A. Scardino, D.A. Gross, P. Alves, J.L. Schultze, S. Graff-Dubois, and O. Faure HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy J Immunol 168 11 2002 5900 5906
19. S. Graff-Dubois, O. Faure, D.A. Gross, P. Alves, A. Scardino, and S. Chouaib Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy J Immunol 169 1 2002 575 580
20. S. Pascolo, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemonnier, and B. Perarnau HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice J Exp Med 185 12 1997 2043 2051
21. S. Tourdot, A. Scardino, E. Saloustrou, D.A. Gross, S. Pascolo, and P. Cordopatis A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-Associated peptides: implication in the identification of cryptic tumor epitopes Eur J Immunol 30 12 2000 3411 3421
22. I. Miconnet, S. Koenig, D. Speiser, A. Krieg, P. Guillaume, and J.C. Cerottini CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide J Immunol 168 3 2002 1212 1218
23. C. Kesmir, A.K. Nussbaum, H. Schild, V. Detours, and S. Brunak Prediction of proteasome cleavage motifs by neural networks Protein Eng 15 4 2002 287 296
24. C. Kuttler, A.K. Nussbaum, T.P. Dick, H.G. Rammensee, H. Schild, and K.P. Hadeler An algorithm for the prediction of proteasomal cleavages J Mol Biol 298 3 2000 417 429
25. A.K. Nussbaum, C. Kuttler, K.P. Hadeler, H.G. Rammensee, and H. Schild PAProC: a prediction algorithm for proteasomal cleavages available on the WWW Immunogenetics 53 2 2001 87 94
26. K.C. Parker, M.A. Bednarek, and J.E. Coligan Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol 152 1 1994 163 175
27. L. Mateo, J. Gardner, Q. Chen, C. Schmidt, M. Down, and S.L. Elliott An HLA-A2 polyepitope vaccine for melanoma immunotherapy J Immunol 163 7 1999 4058 4063
28. G.Y. Ishioka, J. Fikes, G. Hermanson, B. Livingston, C. Crimi, and M. Qin Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes J Immunol 162 7 1999 3915 3925
29. M.J. Palmowski, E.M. Choi, I.F. Hermans, S.C. Gilbert, J.L. Chen, and U. Gileadi Competition between CTL narrows the immune response induced by prime-boost vaccination protocols J Immunol 168 9 2002 4391 4398
30. M.P. Velders, S. McElhiney, M.C. Cassetti, G.L. Eiben, T. Higgins, and G.R. Kovacs Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Res 61 21 2001 7861 7867
31. Q.M. Wang, S.H. Sun, Z.L. Hu, F.J. Zhou, M. Yin, and C.J. Xiao Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine Scand J Immunol 60 3 2004 219 225
32. M.P. Velders, S. Weijzen, G.L. Eiben, A.G. Elmishad, P.M. Kloetzel, and T. Higgins Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol 166 9 2001 5366 5373
33. B. Livingston, C. Crimi, M. Newman, Y. Higashimoto, E. Appella, and J. Sidney A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes J Immunol 168 11 2002 5499 5506
34. R.F. Wang, and H.Y. Wang Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells Nat Biotechnol 20 2 2002 149 154
35. A.V. Gett, F. Sallusto, A. Lanzavecchia, and J. Geginat T cell fitness determined by signal strength Nat Immunol 4 4 2003 355 360
36. S. Zwaveling, S.C. Ferreira Mota, J. Nouta, M. Johnson, G.B. Lipford, and R. Offringa Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J Immunol 169 1 2002 350 358